Background
Actinic keratosis (AK) reflects a field cancerization process in chronically sun-damaged skin, and relapse after diclofenac therapy is a frequent clinical scenario. Field-directed treatments such as 5-fluorouracil (5-FU), tirbanibulin, and photodynamic therapy (PDT) are widely used, yet comparative data in post-diclofenac relapse and the contribution of reflectance confocal microscopy (RCM) to therapeutic monitoring remain limited.
Objectives
To compare the clinical efficacy, tolerability, and subclinical response of 5-FU 4%, tirbanibulin 1%, and PDT in relapsing AK of the scalp, integrating RCM imaging to assess field response.
Methods
A prospective randomized (1:1:1) study was conducted in 45 patients who previously achieved complete clearance with diclofenac 3% and relapsed within 12 months. Endpoints included clinical clearance at 12 weeks, RCM normalization, recurrence at 6 months, and local skin response (LSR) severity.
Results
Twelve-week clearance rates were 73.3% for 5-FU, 66.7% for tirbanibulin, and 80.0% for PDT (p=0.711). RCM normalization occurred in 66.7%, 60.0%, and 73.3% of patients, respectively (p=0.741). Recurrence among responders at 6 months was low and comparable (9.1%, 10.0%, and 8.3%; p=0.991). Tirbanibulin showed significantly lower LSR scores versus 5-FU and PDT (p<0.001), indicating superior tolerability.
Conclusions
Short-term efficacy of 5-FU, tirbanibulin, and PDT was comparable, while tolerability differed markedly. Tirbanibulin demonstrated the most favorable inflammatory and cosmetic profile, whereas 5-FU and PDT may be preferred when a more intense field effect is desired. RCM detected subclinical persistence in select cases and may serve as an adjunctive imaging tool for monitoring and guiding retreatment in field cancerization.
扫码关注我们
求助内容:
应助结果提醒方式:
